Clinical Trial Update: A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI [Phase 4]

View source ↗

Summary

This clinical trial update reports Phase 4 results from a two-dose level study of Naglazyme (galsulfase) in infants with Mucopolysaccharidosis type VI.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Maroteaux-lamy Syndrome
• Mucopolysaccharidosis Type Vi

Drugs mentioned

• NAGLAZYME (GALSULFASE)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Mucopolysaccharidosis VI, Maroteaux-Lamy Syndrome | Phase 4 | Status: COMPLETED | Results posted: 2010-10-15